Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Dennis A. Ostwald"'
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
IntroductionInnovative medicines and vaccines can provide direct health benefits to patients and populations by preventing, treating and curing diseases, and also drive wider socioeconomic and productivity gains. However, researching and developing t
Externí odkaz:
https://doaj.org/article/ed97453fe4a64c2389d9a49f797198e9
Autor:
Foteini Tsotra, Mathias Kappel, Platon Peristeris, Giovanni Bader, Eva Levi, Nicola Lister, Ankur Malhotra, Dennis A Ostwald
Publikováno v:
Journal of Comparative Effectiveness Research. 11:1185-1199
Aim: The current study estimates the societal impact of early intensified treatment compared with initial monotherapy with subsequent treatment intensification in newly diagnosed adults with type 2 diabetes mellitus in Mexico. Methods: An individual
Publikováno v:
Value in Health.
Autor:
Sarah Hofmann, Aino Launonen, Sebastian Himmler, Per-Olof Thuresson, Ulrich Dünzinger, Dennis A Ostwald
Publikováno v:
Journal of Comparative Effectiveness Research. 9:1017-1026
In this study, we assessed the productivity gains associated with the use of obinutuzumab in combination with chemoimmunotherapy (G-chemo) in first-line treatment among follicular lymphoma patients. Health benefits, measured as an increase in progres
Autor:
Dennis A Ostwald, Afschin Gandjour
Publikováno v:
Applied Health Economics and Health Policy. 18:109-125
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that occurs in people affected by the autoimmune disease psoriasis. The cost effectiveness of secukinumab in PsA has not been evaluated in Germany. The purpose of this study was to conduct
Publikováno v:
PharmacoEconomics - open. 6(2)
Objectives Moderate to severe plaque psoriasis is a chronic inflammatory disease. In Germany, guidelines recommend fumaric acid esters (FAEs) as first-line systemic treatment. Despite treatment with FAEs, disease burden remains high in Germany. Secuk
Autor:
Zaza Katsarava, Sara Schramm, Ahmed H Seddik, Claudio Schiener, Dennis A Ostwald, Jasper Huels
Objectives Migraine is a highly prevalent neurological disorder. The most characteristic symptom of migraine is moderate to severe recurrent headache along with other neurological symptoms. In this study, we modeled the potential reduction in migrain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92d97ecc7574c0e4b2ad7885a0c69655
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85111330931
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85111330931
Publikováno v:
Journal of comparative effectiveness research. 10(2)
Aim: This study estimates the societal benefits of using biologics like secukinumab (SEC) instead of nonsteroidal anti-inflammatory drugs for treating patients with ankylosing spondylitis in Germany. Materials & methods: A Markov and a population mod
Autor:
Ahmed H Seddik, Martin Bierbaum, Dennis A Ostwald, Zaza Katsarava, Sara Schramm, Jennifer C Branner
Publikováno v:
Cephalalgia : an international journal of headache. 40(14)
Background This study estimates the socioeconomic impact of migraine headaches on paid and unpaid work productivity in the adult German population in 1 year. Methods We used data on headache frequency (days per month) from a longitudinal population-b
Publikováno v:
The European Journal of Health Economics
Background In Germany, several triplet therapies for treating relapsed or refractory multiple myeloma (rrMM) patients have recently been approved. While most of them are administered intravenously, ixazomib-based combination is the only orally bioava